Deakin University
Browse
berk-potentialof-2019.pdf (822.49 kB)

The potential of carnosine in brain-related disorders: A comprehensive review of current evidence

Download (822.49 kB)
Version 3 2024-06-18, 15:07
Version 2 2024-06-03, 19:33
Version 1 2019-06-14, 14:13
journal contribution
posted on 2024-06-18, 15:07 authored by M Schön, A Mousa, Michael BerkMichael Berk, WL Chia, J Ukropec, A Majid, B Ukropcová, B De Courten
Neurological, neurodegenerative, and psychiatric disorders represent a serious burden because of their increasing prevalence, risk of disability, and the lack of effective causal/disease-modifying treatments. There is a growing body of evidence indicating potentially favourable effects of carnosine, which is an over-the-counter food supplement, in peripheral tissues. Although most studies to date have focused on the role of carnosine in metabolic and cardiovascular disorders, the physiological presence of this di-peptide and its analogues in the brain together with their ability to cross the blood-brain barrier as well as evidence from in vitro, animal, and human studies suggest carnosine as a promising therapeutic target in brain disorders. In this review, we aim to provide a comprehensive overview of the role of carnosine in neurological, neurodevelopmental, neurodegenerative, and psychiatric disorders, summarizing current evidence from cell, animal, and human cross-sectional, longitudinal studies, and randomized controlled trials.

History

Journal

Nutrients

Volume

11

Article number

ARTN 1196

Pagination

1 - 26

Location

Switzerland

Open access

  • Yes

ISSN

2072-6643

eISSN

2072-6643

Language

English

Publication classification

C1 Refereed article in a scholarly journal

Copyright notice

2019, the authors

Issue

6

Publisher

MDPI